106 results about "Viremia" patented technology

A method of predicting the virulence of a new or uncharacterized PRRS virus isolate is provided wherein the isolate is injected into swine and allowed to replicate for a period of from about 3-15 days. During this period, the rate of virus growth and / or the magnitude of viremia is determined, and this data is compared with a corresponding growth rate and / or viremia magnitude of a PRRS virus isolate of known virulence, as a measure of the virulence of the new or uncharacterized isolate. Additionally, a method of selecting an isolate for inclusion in an immunogenic composition based on the predicted virulence is also provided, together with compositions incorporating attenuated forms of viruses predicted to be virulent.

A method of predicting the virulence of a new or uncharacterized PRRS virus isolate is provided wherein the isolate is injected into swine and allowed to replicate for a period of from about 3-15 days. During this period, the rate of virus growth and / or the magnitude of viremia is determined, and this data is compared with a corresponding growth rate and / or viremia magnitude of a PRRS virus isolate of known virulence, as a measure of the virulence of the new or uncharacterized isolate. Additionally, a method of selecting an isolate for inclusion in an immunogenic composition based on the predicted virulence is also provided, together with compositions incorporating attenuated forms of viruses predicted to be virulent.

A method of predicting the virulence of a new or uncharacterized PRRS virus strain is provided wherein the strain is injected into swine and allowed to replicate for a period of from about 3-15 days. During this period, the rate of virus growth and / or the magnitude of viremia is determined, and this data is compared with a corresponding growth rate and / or viremia magnitude of a PRRS virus strain of known virulence, as a measure of the virulence of the new or uncharacterized strain.

Previously, we showed that type I interferon (alpha / beta interferon [IFN-α / β]) can inhibit foot-and-mouth disease virus (FMDV) replication in cell culture, and swine inoculated with 109 PFU of human adenovirus type 5 expressing porcine IFN-α (Ad5-pIFN-α) were protected when challenged 1 day later. In this study, we found that type II pIFN (pIFN-γ) also has antiviral activity against FMDV in cell culture and that, in combination with pIFN-α, it has a synergistic antiviral effect. We also observed that while each IFN alone induced a number of IFN-stimulated genes (ISGs), the combination resulted in a synergistic induction of some ISGs. To extend these studies to susceptible animals, we inoculated groups of swine with a control Ad5, 108 PFU of Ad5-pIFN-α, low- or high-dose Ad5-pIFN-γ, or a combination of Ad5-pIFN-α and low- or high-dose Ad5-pIFN-γ and challenged all groups with FMDV 1 day later. The control group and the groups inoculated with either Ad5-pIFN-α or a low dose of Ad5-pIFN-γ developed clinical disease and viremia. However, the group that received the combination of both Ad5-IFNs with the low dose of Ad5-pIFN-γ was completely protected from challenge and had no viremia. Similarly the groups inoculated with the combination of Ad5s with the higher dose of Ad5-pIFN-γ or with only high-dose Ad5-pIFN-γ were protected. The protected animals did not develop antibodies against viral nonstructural (NS) proteins, while all infected animals were NS protein seropositive. No antiviral activity or significant levels of IFNs were detected in the protected groups, but there was an induction of some ISGs. The results indicate that the combination of type I and II IFNs act synergistically to inhibit FMDV replication in vitro and in vivo.

The invention discloses a RT-LAMP (reverse transcription loop-mediated isothermal amplification) detection kit and a RT-LAMP detection method for SVCV (spring viremia of carp virus). The RT-LAMP detection kit of SVCV comprises 10*ThermoPol Reaction buffer, Bst DNA (deoxyribonucleic acid) polymerase, dNTPs (deoxynucleoside triphosphates), AMV reverse transcriptase, outer primer F3 and B3, inner primer FIP, BIP and Betaine, MgC 12, DTT, and 1000*SYBR Green I. The RT-LAMP detection kit is simple, fast, and high in specificity and sensitivity, only needs a water bath kettle or a metal bath to accurately detect SVCV in samples in 2 hours, can detect SVCV of infected tissues of sick fish, can detect cells infected by SVCV, and is suitable for fast field detection of SVCV.

The invention relates to the technical field of porcine circovirus, in particular to a porcine circovirus 2 (PCV2) immune protection polypeptide, and a vaccine containing the PCV2 immune protection polypeptide. The amino acid sequence of the PCV2 immune protection polypeptide is shown in the sequence table 1-4. According to the vaccine, tests show that after 42-63 days of first immune of a vaccine of P5013 and a vaccine of P1300, the antibody titer and the neutralizing antibody titer of an ELISA antibody are remarkably increased, the lymphocyte proliferative response and IL-4 and IFN-Gamma cytokines are significantly higher than those of a control group, and the antibody level and the cellular immunity level of the vaccine group of P5013 are the highest; mice tests show that PCV2 immune response induced by the synthetic peptide vaccine of P5013 is the highest and the strongest; pig tests find that the synthetic polypeptide vaccine of P5013 can induce pigs to generate a PCV2-specific immune response, can reduce viremia caused by PCV2 virulent virus attack, alleviate the clinical symptoms and pathological lesions of viremia, and has immune protection effect on PCV2.

The invention discloses an application of calcium lactate in preparation of a medicine for preventing and treating infection caused by spring viremia of carp virus (SVCV). An experimental animal infection model proves that calcium lactate can play a role in treating SVCV-caused infection of zebra fish, virus proliferation and qPCR experiments are combined to find that the expression quantity of virus-related genes after calcium lactate treatment is obviously reduced, so that calcium lactate can be used as a medicine for preventing and treating SVCV and has the advantages of low dosage, safetyand no toxic or side effect.

The invention discloses a carp spring viremia virus detection kit based on pyrosequencing. The carp spring viremia virus detection kit based on the pyrosequencing depends on a carp spring viremia virus fingerprint sequence, and the carp spring viremia virus fingerprint sequence is nucleotides at the 511th-526th positions of SEQ ID No.1 shown in a sequence table. The kit comprises a sequencing primer of the carp spring viremia virus fingerprint sequence and a primer pair for amplifying the carp spring viremia virus fingerprint sequence. The sequencing primer is single-stranded DNA represented by SEQ ID No.4 shown in the sequence table. The primer pair for amplifying the carp spring viremia virus fingerprint sequence consists of single-stranded DNA represented by SEQ ID No.2 shown in the sequence table and single-stranded DNA represented by SEQ ID No.3 shown in the sequence table.

The invention belongs to the field of molecular biology, and discloses a new porcine reproductive and respiratory syndrome virus ORF5 modified gene and an application thereof. The porcine reproductive and respiratory syndrome virus ORF5 modified gene has a sequence as shown in SEQ IDNO. 2, SEQ IDNO. 3, SEQ IDNO. 4, or SEQ IDNO. 5. A recombinant plasmid containing the porcine reproductive and respiratory syndrome virus ORF5 modified gene is provided. Attenuated salmonella SL-pCI-SynGP5 / GP4-5 containing the recombinant plasmid is provided. Results show that the constructed recombinant plasmid can induce high-level humoral immune response, lymphocyte proliferation response, and cytokine response. the recombinant salmonella can induce high-level antibody response, and induce high-level interferon; the viremia level is low; the damage of tissues and organs after toxin attack is relatively slight, and the biosafety level is high.

The invention discloses a gene-deleted attenuated African swine fever virus strain, a construction method and application thereof, and belongs to the technical field of biological vaccine products. The gene-deleted attenuated African swine fever virus strain constructed by the homologous recombination method of the present invention is based on the type II African swine fever virus genome and simultaneously deletes CD2v, MGF (12L, 13L, 14L) and I177L gene fragments The gene deletion virus strain is obviously attenuated relative to the parental strain, and will not affect the stable replication and immunogenicity of the gene deletion virus strain. After being inoculated into experimental pigs, there will be no obvious rise in body temperature, joint swelling, disease or death of experimental pigs, and no viremia, showing good safety and good immune challenge protection effect. Therefore, the gene-deleted attenuated African swine fever virus strain provided by the present invention can be used as a candidate vaccine strain with good safety and immune protection effect.

GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.